Watermark
  Back to Search Results

BGB-A317-214

Completed

Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer

BeOne Study ID Info icon SVG graphic used for tooltips or additional information.

BGB-A317-214

ClinicalTrials.gov ID Info icon SVG graphic used for tooltips or additional information.

NCT05116085

China Drug Trials ID Info icon SVG graphic used for tooltips or additional information.

CTR20212779

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Study Protocol Statistical Analysis Plan